Company intelligence / Profile preview
Microvascular Therapeutics
Tucson, Arizona, United Statesmvtpharma.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
MVT-100 is in Phase 1/2 clinical trials for echocardiography via the 505(b)(2) regulatory pathway. MVT-101 is completing late-preclinical GLP studies for deep vein thrombosis and pulmonary emboli indications.
- Therapeutic areas
- OphthalmologyOncologyCardiovascularNeurology
- Modalities
- Microbubble technologyNanobubble technologyUltrasound contrast agentsTheranostics
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
03
Partnerships
Cordance Medical (strategic partnership announced September 16, 2024)
Beyond the preview
Go deeper on Microvascular Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Microvascular Therapeutics.